抗精神病薬
(Antipsychotic から転送)
出典: フリー百科事典『ウィキペディア（Wikipedia）』 (2024/01/30 03:39 UTC 版)
抗精神病薬（こうせいしんびょうやく、英語: Antipsychotics）は、広義の向精神薬の一種[注釈 1]で、主に統合失調症などの症状を緩和する精神科の薬である[1][2]。過去には、神経遮断薬 (Neuroleptics)[3]、あるいはメジャートランキライザー (Major tranquilizers) とも呼ばれ、1950年代には単にトランキライザーと呼ばれた。薬事法における劇薬に指定されるものが多い。抗精神病薬は、それ以外にも幅広い精神障害に使用される。精神科の薬というのはこの抗精神病薬のことを指す。代表的な薬品として、クロルプロマジンやハロペリドールなどがある。
注釈
- ^ 抗精神病薬は、通常、向精神薬のカテゴリに含まれる薬剤として扱われる。（参考：厚生労働省平成22年9月10日障精発0910第1号「向精神薬等の過量服薬への取組について」においての「向精神薬(抗うつ薬、抗不安薬、睡眠薬、抗精神病薬)」の記述など （参照（厚生労働省法令データベースサービス）））
- ^ 原文: “psychotropic medication can have profound and lasting negative effects on a patient's mind and body” [144][145][146][147]
- ^ 原文: “are known to cause a number of potentially devastating side effects.” [144][145][146][147]
出典
- ^ a b c d e f g h i j k l m 世界保健機関 2010, PSY.
- ^ a b 世界保健機関 2010, BPD.
- ^ a b c d e アメリカ精神医学会『DSM-5 精神疾患の診断・統計マニュアル』日本精神神経学会日本語版用語監修・高橋三郎・大野裕監訳・染矢俊幸・神庭重信・尾崎紀夫・三村將・村井俊哉訳、医学書院、2014年6月30日、703-707頁。ISBN 978-4260019071。
- ^ Mitchell, A. J.; Delaffon, V.; Vancampfort, D.; Correll, C. U.; De Hert, M. (January 2011). “Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices”. Psychological Medicine 42 (01): 125–147. doi:10.1017/S003329171100105X. PMID 21846426.
- ^ a b Wunderink, Lex; Nieboer, Roeline M.; Wiersma, Durk; Sytema, Sjoerd; Nienhuis, Fokko J. (September 2013). “Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy” (pdf). JAMA Psychiatry 70 (9): 913. doi:10.1001/jamapsychiatry.2013.19. PMID 23824214.
- ^ 厚生労働省『精神科医療について』（pdf）（プレスリリース）2011年11月2日、111-113頁。2013年7月11日閲覧。
- ^ 厚生労働省自殺・うつ病等対策プロジェクトチーム『過量服薬への取組－薬物治療のみに頼らない診療体制の構築に向けて』（pdf）（プレスリリース）2010年9月9日、7-8頁。2013年3月15日閲覧。
- ^ 『抗精神病薬減量法ガイドラインを発表 -多剤大量処方から少しずつ最適な処方への工夫』（プレスリリース）独立行政法人国立精神・神経医療研究センター、2013年10月4日。
- ^ a b 田辺英 著「60 抗精神病薬の離脱症状について教えてください。」、藤井康男(編集)、稲垣中(編集協力) 編『統合失調症の薬物療法100のQ&A』星和書店、2008年5月、194-195頁。ISBN 978-4791106677。
- ^ a b Huhtaniska, Sanna; Jääskeläinen, Erika; Hirvonen, Noora; et al. (2017). “Long-term antipsychotic use and brain changes in schizophrenia - a systematic review and meta-analysis”. Human Psychopharmacology: Clinical and Experimental 32 (2): e2574. doi:10.1002/hup.2574. PMID 28370309.
- ^ a b Nordström, Peter; Nordström, Anna; Eriksson, Marie; Wahlund, Lars-Olof; Gustafson, Yngve (September 2013). “Risk Factors in Late Adolescence for Young-Onset Dementia in Men” (pdf). JAMA Internal Medicine 173 (17): 1612. doi:10.1001/jamainternmed.2013.9079. PMID 23939347.
- ^ a b Kapur, S. (April 2000). “Relationship Between Dopamine D2 Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia”. American Journal of Psychiatry 157 (4): 514–520. doi:10.1176/appi.ajp.157.4.514. PMID 10739409.。
- ^ a b c d e f Maia Szalavitz Sept (2012年9月17日). “Top 10 Drug Company Settlements”. TIME.com 2013年2月23日閲覧。
- ^ 英国国立医療技術評価機構 2014, Chapt.1.3.4.
- ^ 英国国立医療技術評価機構 2014, Chapt.1.3.2.1.
- ^ 英国国立医療技術評価機構 2014, Chapt.1.2.3.2.
- ^ 英国国立医療技術評価機構 2014b, Chapt.1.10.13.
- ^ a b 英国国立医療技術評価機構 (November 2006). CG42 - Dementia: Supporting people with dementia and their carers in health and social care (Report). Chapt.1.7.
- ^ 王立オーストラリア総合医学会 (2006-03), Medical care of older persons in residential aged care facilities (silver book), The Royal Australian College of General Practitioners, p. 32, ISBN 0-86906-212-3
- ^ アメリカ精神医学会 (September 2013). Five Things Physicians and Patients Should Question. Choosing Wisely (Report). ABIM Foundation.
- ^ QS53 - Anxiety disorders (Report). 英国国立医療技術評価機構. February 2014. Quality statement 3.
- ^ Bellack AS (July 2006). “Scientific and Consumer Models of Recovery in Schizophrenia: Concordance, Contrasts, and Implications”. Schizophrenia Bulletin 32 (3): 432–42. doi:10.1093/schbul/sbj044. PMC 2632241. PMID 16461575.
- ^ Mangrella M, Motola G, Russo F et al. (1998). “[Intensive hospital monitoring of adverse reactions to benzodiazepines and neuroleptic agents]” (Italian). Minerva Medica 89 (7–8): 293–300. PMID 9824992.
- ^ Healy 2009, p42. Psychiatric drugs explained 5th ED. Edinburgh : Elsevier Churchill Livingstone
- ^ Artaloytia, J. F. (March 2006). “Negative Signs and Symptoms Secondary to Antipsychotics: A Double-Blind, Randomized Trial of a Single Dose of Placebo, Haloperidol, and Risperidone in Healthy Volunteers”. American Journal of Psychiatry 163 (3): 488–493. doi:10.1176/appi.ajp.163.3.488. PMID 16513871.
- ^ Weinmann, Stefan; Read, John; Aderhold, Volkmar (August 2009). “Influence of antipsychotics on mortality in schizophrenia: Systematic review”. Schizophrenia Research 113 (1): 1–11. doi:10.1016/j.schres.2009.05.018. PMID 19524406.
- ^ a b Joukamaa, M. (February 2006). “Schizophrenia, neuroleptic medication and mortality”. The British Journal of Psychiatry 188 (2): 122–127. doi:10.1192/bjp.188.2.122. PMID 16449697.
- ^ “Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances”. FDA (2005年4月11日). 2013年3月20日閲覧。
- ^ a b Glever, J (2008年). “Boxed Mortality Warning Added to Older Antipsychotics Given to Elderly Demented”. Medpage Today 2009年4月24日閲覧。
- ^ Kales, Helen C.; Kim, Hyungjin Myra; Zivin, Kara; Valenstein, Marcia; Seyfried, Lisa S.; Chiang, Claire; Cunningham, Francesca; Schneider, Lon S. et al. (January 2011). “Risk of Mortality Among Individual Antipsychotics in Patients With Dementia”. The American Journal of Psychiatry 169 (1): 71–9. doi:10.1176/appi.ajp.2011.11030347. PMID 22193526.
- ^ Schneider-Thoma J, Efthimiou O, Huhn M, et al. (August 2018). “Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials”. Lancet Psychiatry (8): 653–663. doi:10.1016/S2215-0366(18)30177-9. PMID 30042077.
- ^ Fourrier-Réglat, Annie (April 2012). “Antipsychotic Use and Myocardial Infarction in Older Patients With Treated Dementia”. Archives of Internal Medicine 172 (8): 648. doi:10.1001/archinternmed.2012.28. PMID 22450214.
- ^ Trifirò G, Gambassi G, Sen EF, Caputi AP, Bagnardi V, Brea J, Sturkenboom MC (April 2010). “Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study”. Annals of Internal Medicine 152 (7): 418–25, W139–40. doi:10.1059/0003-4819-152-7-201004060-00006. PMID 20368647.
- ^ a b Schizophrenia Drugs May Spur Subtle Brain Tissue Loss. Drugs.com.
- ^ Ho, Beng; Andreasen, Nancy C.; Ziebell, Stephen; Pierson, Ronald; Magnotta, Vincent (Feb. 2011). “Long-term antipsychotic treatment and brain volumes: a longtitudinal study of first-episode schizophrenia”. Archives of General Psychiatry 68 (2): 128–37. doi:10.1001/archgenpsychiatry.2010.199. PMC 3476840. PMID 21300943 2011年4月5日閲覧。.
- ^ lewis, David A (Feb. 2011). “Antipsychotic medications and brain volume: do we have a cause for concern?”. Archives of General Psychiatry 68 (2): 126–27. doi:10.1001/archgenpsychiatry.2010.187.
- ^ 抗精神病薬による脳への負の影響。その1 灰白質への影響 場末Ｐ科病院の精神科医のblog
- ^ 抗精神病薬による脳への負の影響。その2 白質への影響 場末Ｐ科病院の精神科医のblog
- ^ Dorph-Petersen, Karl-Anton; Pierri, Joseph N; Perel, James M; Sun, Zhuoxin; Sampson, Allan R; Lewis, David A (2005). “The Influence of Chronic Exposure to Antipsychotic Medications on Brain Size before and after Tissue Fixation: A Comparison of Haloperidol and Olanzapine in Macaque Monkeys”. Neuropsychopharmacology 30 (9): 1649–1661. doi:10.1038/sj.npp.1300710. ISSN 0893-133X.
- ^ Radua, J.; Borgwardt, S.; Crescini, A.; Mataix-Cols, D.; Meyer-Lindenberg, A.; McGuire, P.K.; Fusar-Poli, P. (November 2012). “Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication”. Neuroscience & Biobehavioral Reviews 36 (10): 2325–2333. doi:10.1016/j.neubiorev.2012.07.012. PMID 22910680.
- ^ Zonnenberg C, Bueno-de-Mesquita JM, Ramlal D, Blom JD (2017). “Hypothermia due to Antipsychotic Medication: A Systematic Review”. Front Psychiatry: 165. doi:10.3389/fpsyt.2017.00165. PMC 5594062. PMID 28936184.
- ^ Ruchita Shah; Sandeep Grover; Uma Maheshwari; Natasha Kate; Nidhi Malhotra (2010). “Acute akathisia with quetiapine: A case report and review of literature”. Indian Journal of Pharmacology. PMC 2991706.
- ^ Weston-Green, K; Huang XF, Lian JM, Deng C (May 2012). “Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels”. European Neuropsychopharmacology 22 (5): 364–73. doi:10.1016/j.euroneuro.2011.09.003. PMID 21982116.
- ^ Ruiz de Azua, I; Gautam D; Guettier JM; Wess J (February 2011). “Novel insights into the function of [beta-cell M3 muscarinic acetylcholine receptors: therapeutic implications”]. Trends in Endocrinology & Metabolism 22 (2): 74–80. doi:10.1016/j.tem.2010.10.004. PMC 3053051. PMID 21106385.
- ^ Torrey EF, Swalwell CI (December 2003). “Fatal olanzapine-induced ketoacidosis”. The American Journal of Psychiatry 160 (12): 2241. doi:10.1176/appi.ajp.160.12.2241. PMID 14638601.
- ^ Koller EA, Doraiswamy PM (July 2002). “Olanzapine-associated diabetes mellitus”. Pharmacotherapy 22 (7): 841–52. doi:10.1592/phco.22.11.841.33629. PMID 12126218.
- ^ Koller EA, Cross JT, Doraiswamy PM, Malozowski SN (September 2003). “Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports”. Pharmacotherapy 23 (9): 1123–30. doi:10.1592/phco.23.10.1123.32759. PMID 14524644.
- ^ Deng, C; Weston-Green K; Huang XF (2010-02-01). “The role of histaminergic H1 and H3 receptors in food intake: A mechanism for atypical antipsychotic-induced weight gain?”. Progress in Neuro-Psychopharmacology and Biological Psychiatry 34 (1): 1–4. doi:10.1016/j.pnpbp.2009.11.009. PMID 19922755.
- ^ Weston-Green, K; Huang XF, Deng C (2012-03-16). Chang, Alice Y. W. ed. “Alterations to Melanocortinergic, GABAergic and Cannabinoid Neurotransmission Associated with Olanzapine-Induced Weight Gain”. PLoS One 7 (3): e33548. doi:10.1371/journal.pone.0033548. PMC 3306411. PMID 22438946.
- ^ Hasnain M, Vieweg WVR, Fredrickson SK (2010). “Metformin for Atypical Antipsychotic-Induced Weight Gain and Glucose Metabolism Dysregulation: Review of the Literature and Clinical Suggestions”. CNS Drugs 24 (3): 193–206. doi:10.2165/11530130-000000000-00000. PMID 20155995.
- ^ Weston-Green, K; Huang XF, Deng C (February 2010). “Sensitivity of the female rat to olanzapine-induced weight gain--far from the clinic?”. Schizophrenia Research 116 (2–3): 299–300. doi:10.1016/j.schres.2009.09.034. PMID 19840894.
- ^ Baldessarini, Ross J.; Frank I. Tarazi (2006). “Pharmacotherapy of Psychosis and Mania”. In Laurence Brunton, John Lazo, Keith Parker (eds.). Goodman & Gilman's The Pharmacological Basis of Therapeutics (11th ed.). New York: McGraw-Hill. ISBN 978-0-07-142280-2. OCLC 150149056[要ページ番号]
- ^ “FDA Drug Safety Communication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns”. FDA (2011年2月22日). 2013年1月27日閲覧。
- ^ 上平忠一「精神分裂病における知覚変容発作の臨床的研究 : 自験例を中心にして」『長野大学紀要』第23巻第1号、長野大学、2001年6月30日、10-21頁、CRID 1050564287518429952、ISSN 0287-5438、NAID 40004066379。
- ^ “Antipsychotic-induced paroxysmal perceptual alteration in a patient with major depressive disorder”. Psychiatry and Clinical Neurosciences 63 (3): 429–430. (June 2009). doi:10.1111/j.1440-1819.2009.01963.x. PMID 19566782.
- ^ Bozkurt, Hasan; Ayaydın, Hamza; Adak, İbrahim; Zoroğlu, S. Salih (December 2012). “Risperidone-Induced Paroxysmal Perceptual Alteration in a Child with Autism”. Journal of Child and Adolescent Psychopharmacology 22 (6): 470–471. doi:10.1089/cap.2012.0053. PMID 23234592.
- ^ 統合失調症の薬物療法100のQ&A 星和書店 p.281
- ^ Dilsaver, SC.; Alessi, NE. (Mar 1988). “Antipsychotic withdrawal symptoms: phenomenology and pathophysiology”. Acta Psychiatr Scand 77 (3): 241–6. doi:10.1111/j.1600-0447.1988.tb05116.x. PMID 2899377.
- ^ a b c d Moncrieff, J. (2006). “Why is it so difficult to stop psychiatric drug treatment? It may be nothing to do with the original problem”. Med Hypotheses 67 (3): 517–23. doi:10.1016/j.mehy.2006.03.009. PMID 16632226.
- ^ Glazer, WM. (2000). “Expected incidence of tardive dyskinesia associated with atypical antipsychotics”. J Clin Psychiatry 61 Suppl 4: 21–6. PMID 10739327.
- ^ Samaha A-N, Seeman P, Stewart J, Rajabi H, Kapur S (2007). “"Breakthrough" Dopamine Supersensitivity during Ongoing Antipsychotic Treatment Leads to Treatment Failure over Time”. The Journal of Neuroscience 27 (11): 2979–2986. doi:10.1523/JNEUROSCI.5416-06.2007. PMID 17360921.
- ^ Gitlin, Michael; Nuechterlein, Keith; Subotnik, Kenneth L.; Ventura, Joseph; Mintz, Jim; Fogelson, David L.; Bartzokis, George; Aravagiri, Manickam (2001). “Clinical Outcome Following Neuroleptic Discontinuation in Patients With Remitted Recent-Onset Schizophrenia”. American Journal of Psychiatry 158 (11): 1835–1842. doi:10.1176/appi.ajp.158.11.1835. ISSN 0002-953X.
- ^ Lambert, TJ. (2007). “Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes”. J Clin Psychiatry 68 Suppl 6: 10–3. PMID 17650054.
- ^ “Medical Term: cross-taper”. Drugs.com. 2013年4月10日閲覧。
- ^ Group, BMJ, ed. (2009-03), “4.2.1”, British National Formulary (57 ed.), United Kingdom: 王立薬剤師会, p. 192, ISBN 978-0853698456, "Withdrawal of antipsychotic drugs after long-term therapy should always be gradual and closely monitored to avoid the risk of acute withdrawal syndromes or rapid relapse."
- ^ Antipsychotics en:David Healy (psychiatrist) - 2016年12月14日閲覧
- ^ 姫井昭男『精神科の薬がわかる本』（1版）医学書院、2008年、113頁。ISBN 978-4-260-00763-4。
- ^ 笠陽一郎『精神科セカンドオピニオン―正しい診断と処方を求めて』シーニュ、2008年7月、204-206頁。ISBN 978-4-9903014-1-5。
- ^ 山田武史 著「12 抗コリン性抗パーキンソン薬について教えて下さい。抗コリン性パーキンソン病を併用することによるデメリットはどのようなものがあるでしょうか？本当に認知機能に影響するのでしょうか？」、藤井康男(編集)、稲垣中(編集協力) 編『統合失調症の薬物療法100のQ&A』星和書店、2008年5月、35-37頁。ISBN 978-4791106677。
- ^ 精神医学講座担当者会議、佐藤光源、丹羽真一、井上新平『統合失調症治療ガイドライン』（2版）医学書院、2008年、133頁。ISBN 978-4-260-00646-0。
- ^ “Practice Guideline for the Treatment of Patients With Schizophrenia Second Edition”. The American Journal of Psychiatry 1 (2 Suppl): 1–56. (February 2006). doi:10.1176/appi.books.9780890423363.45859. PMID 15000267.[リンク切れ]
- ^ Adams, C. E. (2004). “Schizophrenia. Full National Clinical Guideline on Core Interventions in Primary and Secondary Care National Collaborating Centre for Mental Health”. Psychiatric Bulletin 28 (9): 351–351. doi:10.1192/pb.28.9.351. ISSN 0955-6036.
- ^ Leucht, S; Arbter, D; Engel, R R; Kissling, W; Davis, J M (April 2008). “How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials”. Molecular Psychiatry 14 (4): 429–447. doi:10.1038/sj.mp.4002136. PMID 18180760.
- ^ Rattehalli, Ranganath D; Jayaram, Mahesh B; Smith, Michael; Rattehalli, Ranganath D (2010). Risperidone versus placebo for schizophrenia. doi:10.1002/14651858.CD006918.pub2.
- ^ Cipriani A, Rendell JM, Geddes J (2009). Cipriani, Andrea. ed. “Olanzapine in long-term treatment for bipolar disorder”. Cochrane Database of Systematic Reviews (Online) (1): CD004367. doi:10.1002/14651858.CD004367.pub2. PMID 19160237.
- ^ a b Hay, Phillipa J.; Spielmans, Glen I.; Berman, Margit I.; Linardatos, Eftihia; Rosenlicht, Nicholas Z.; Perry, Angela; Tsai, Alexander C. (2013). “Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes”. PLoS Medicine 10 (3): e1001403. doi:10.1371/journal.pmed.1001403.
- ^ Patrick V, Levin E, Schleifer S (July 2005). “Antipsychotic polypharmacy: is there evidence for its use?”. Journal of Psychiatric Practice 11 (4): 248–57. doi:10.1097/00131746-200507000-00005. PMID 16041235.
- ^ Ito H, Koyama A, Higuchi T (September 2005). “Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription”. The British Journal of Psychiatry 187 (3): 243–7. doi:10.1192/bjp.187.3.243. PMID 16135861.
- ^ a b Grunder, G.; Fellows, C.; Janouschek, H.; Veselinovic, T.; Boy, C.; Brocheler, A.; Kirschbaum, K. M.; Hellmann, S. et al. (August 2008). “Brain and Plasma Pharmacokinetics of Aripiprazole in Patients With Schizophrenia: An [18FFallypride PET Study”]. American Journal of Psychiatry 165 (8): 988–995. doi:10.1176/appi.ajp.2008.07101574. PMID 18381901.
- ^ Ezewuzie, N. (January 2005). “Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia”. Journal of Psychopharmacology 20 (1): 86–90. doi:10.1177/0269881105057001. PMID 16174679.
- ^ Sparshatt, Anna; Jones, Sarah; Taylor, David (2008). “Quetiapine: dose-response relationship in schizophrenia”. CNS Drugs 22 (1): 49–68. doi:10.2165/00023210-200822010-00004. PMID 18072814.
- ^ Kinon, Bruce J.; Volavka, Jan; Stauffer, Virginia; Edwards, Sara E.; et al (August 2008). “Standard and Higher Dose of Olanzapine in Patients With Schizophrenia or Schizoaffective Disorder”. Journal of Clinical Psychopharmacology 28 (4): 392–400. doi:10.1097/JCP.0b013e31817e63a5. PMID 18626265.
- ^ Evidence Lacking to Support Many Off-label Uses of Atypical Antipsychotics (2007). Ahrq.gov.
- ^ James, A.C. (2010). “Prescribing antipsychotics for children and adolescents”. Advances in Psychiatric Treatment 16: 63. doi:10.1192/apt.bp.108.005652.
- ^ Romeo R, Knapp M, Tyrer P, Crawford M, Oliver-Africano P (July 2009). “The treatment of challenging behaviour in intellectual disabilities: cost-effectiveness analysis”. Journal of Intellectual Disability Research 53 (7): 633–43. doi:10.1111/j.1365-2788.2009.01180.x. PMID 19460067.
- ^ Clive G Ballard , Jonathan Waite, Jacqueline Birks (2008年10月8日). “Atypical antipsychotics for aggression and psychosis in Alzheimer's disease” (Abstract). The Cochrane Collaboration.. John Wiley & Sons, Ltd.. 2012年7月27日閲覧。
- ^ “NCT00245206 Side Effects of Newer Antipsychotics in Older Adults (NCT00245206)”. ClinicalTrials.gov. 2013年3月24日閲覧。
- ^ Jin, Hua; Shih, Pei-an Betty; Golshan, Shahrokh; Mudaliar, Sunder; Henry, Robert; Glorioso, Danielle K.; Arndt, Stephan; Kraemer, Helena C. et al. (January 2013). “Comparison of Longer-Term Safety and Effectiveness of 4 Atypical Antipsychotics in Patients Over Age 40”. The Journal of Clinical Psychiatry 74 (01): 10–18. doi:10.4088/JCP.12m08001. PMID 23218100.
- ^ Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper J, Day R, Bertelsen A (1992). “Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study”. Psychol Med Monogr Suppl 20: 1–97. doi:10.1017/S0264180100000904. PMID 1565705.
- ^ Hopper K, Wanderling J (2000). “Revisiting the developed versus developing country distinction in course and outcome in schizophrenia: results from ISoS, the WHO collaborative followup project. International Study of Schizophrenia”. Schizophrenia Bulletin 26 (4): 835–46. doi:10.1093/oxfordjournals.schbul.a033498. PMID 11087016.
- ^ Moncrieff J (July 2006). “Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse”. Acta Psychiatrica Scandinavica 114 (1): 3–13. doi:10.1111/j.1600-0447.2006.00787.x. PMID 16774655.
- ^ Harrow M; Jobe TH (May 2007). "Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: a 15-year multifollow-up study". The Journal of Nervous and Mental Disease (英語). 195 (5): 406–414. doi:10.1097/01.nmd.0000253783.32338.6e (inactive 17 March 2010). PMID 17502806。
- ^ Whitaker R (2004). “The case against antipsychotic drugs: a 50-year record of doing more harm than good”. Medical Hypotheses 62 (1): 5–13. doi:10.1016/S0306-9877(03)00293-7. PMID 14728997.
- ^ a b Adam James (2008年3月2日). “Myth of the antipsychotic”. The Guardian. Guardian News and Media Limited. 2012年7月27日閲覧。
- ^ Leucht, S.; Heres, S.; Hamann, J.; Kane, J. M. (March 2008). “Methodological Issues in Current Antipsychotic Drug Trials”. Schizophrenia Bulletin 34 (2): 275–285. doi:10.1093/schbul/sbm159. PMC 2632403. PMID 18234700.
- ^ トーマス・インセル (2013年8月28日). “Antipsychotics: Taking the Long View”. NIMH Director’s Blog. 2014年2月26日閲覧。
- ^ a b c Insel TR (April 2009). “Disruptive insights in psychiatry: transforming a clinical discipline”. J. Clin. Invest. 119 (4): 700–5. doi:10.1172/JCI38832. PMC 2662575. PMID 19339761 2013年1月7日閲覧。.
- ^ a b Peluso, M. J.; Lewis, S. W.; Barnes, T. R. E.; Jones, P. B. (May 2012). “Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs”. The British Journal of Psychiatry 200 (5): 387–392. doi:10.1192/bjp.bp.111.101485. PMID 22442101.
- ^ a b Miller DD, Caroff SN, Davis SM, et al. (October 2008). “Extrapyramidal side-effects of antipsychotics in a randomised trial”. Br J Psychiatry 193 (4): 279–88. doi:10.1192/bjp.bp.108.050088. PMC 2801816. PMID 18827289.
- ^ Ito, Hiroshi; Arakawa, Ryosuke; Takahashi, Hidehiko; Takano, Harumasa; Okumura, Masaki; Otsuka, Tatsui; Ikoma, Yoko; Shidahara, Miho et al. (June 2008). “No regional difference in dopamine D2 receptor occupancy by the second-generation antipsychotic drug risperidone in humans: a positron emission tomography study”. The International Journal of Neuropsychopharmacology 12 (05): 667. doi:10.1017/S1461145708009577. PMID 18937879.
- ^ Geddes J, Freemantle N, Harrison P, Bebbington P (December 2000). “Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis”. BMJ 321 (7273): 1371–6. doi:10.1136/bmj.321.7273.1371. PMC 27538. PMID 11099280.
- ^ a b c d Horacek J, Bubenikova-Valesova V, Kopecek M et al. (2006). “Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia”. CNS Drugs 20 (5): 389–409. doi:10.2165/00023210-200620050-00004. PMID 16696579.
- ^ Leucht S, Wahlbeck K, Hamann J, Kissling W (May 2003). “New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis”. Lancet 361 (9369): 1581–9. doi:10.1016/S0140-6736(03)13306-5. PMID 12747876.
- ^ Davis JM, Chen N, Glick ID (June 2003). “A meta-analysis of the efficacy of second-generation antipsychotics”. Archives of General Psychiatry 60 (6): 553–64. doi:10.1001/archpsyc.60.6.553. PMID 12796218.
- ^ Tuunainen A, Wahlbeck K, Gilbody SM (2000). Tuunainen, Arja. ed. “Newer atypical antipsychotic medication versus clozapine for schizophrenia”. Cochrane Database of Systematic Reviews (2): CD000966. doi:10.1002/14651858.CD000966. PMID 10796559.
- ^ Ghaemi SN, Hsu DJ, Rosenquist KJ, Pardo TB, Goodwin FK (March 2006). “Extrapyramidal side effects with atypical neuroleptics in bipolar disorder”. Progress in Neuro-psychopharmacology & Biological Psychiatry 30 (2): 209–13. doi:10.1016/j.pnpbp.2005.10.014. PMID 16412546.
- ^ Lieberman JA, Stroup TS, McEvoy JP et al. (September 2005). “Effectiveness of antipsychotic drugs in patients with chronic schizophrenia”. The New England Journal of Medicine 353 (12): 1209–23. doi:10.1056/NEJMoa051688. PMID 16172203.
- ^ Meltzer and Bobo (2006) "Interpreting the Efficacy Findings in the CATIE Study: What Clinicians Should Know" CNS Spectr.11(7 Suppl 7):14-24
- ^ Leucht, Stefan; Corves, Caroline; Arbter, Dieter; Engel, Rolf R; Li, Chunbo; Davis, John M (January 2009). “Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis”. The Lancet 373 (9657): 31–41. doi:10.1016/S0140-6736(08)61764-X. PMID 19058842.
- ^ Stroup T; Lieberman, JA; McEvoy, JP; Swartz, MS; Davis, SM; Rosenheck, RA; Perkins, DO; Keefe, RS et al. (2006). “Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic”. Am J Psychiatry 163 (4): 611–22. doi:10.1176/appi.ajp.163.4.611. PMID 16585435.
- ^ McEvoy J; Lieberman, JA; Stroup, TS; Davis, SM; Meltzer, HY; Rosenheck, RA; Swartz, MS; Perkins, DO et al. (2006). “Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia that did not respond to prior atypical antipsychotic treatment”. Am J Psychiatry 163 (4): 600–10. doi:10.1176/appi.ajp.163.4.600. PMID 16585434.
- ^ Voruganti LP, Baker LK, Awad AG (March 2008). “New generation antipsychotic drugs and compliance behaviour”. Current Opinion in Psychiatry 21 (2): 133–9. doi:10.1097/YCO.0b013e3282f52851. PMID 18332660.
- ^ Owens, D. C. (2008). “How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia”. Advances in Psychiatric Treatment 14 (1): 17–28. doi:10.1192/apt.bp.107.003970.
- ^ Typical and Atypical Antipsychotics - The Misleading Dichotomy (2008). Content.karger.com.
- ^ Casey, D (March 1999). “Tardive dyskinesia and atypical antipsychotic drugs”. Schizophrenia Research 35: S61–S66. doi:10.1016/S0920-9964(98)00160-1. PMID 10190226.
- ^ 英国国立医療技術評価機構 2014, Chapt.1.3.5.
- ^ Lieberman JA, Stroup TS, McEvoy JP, et al. (September 2005). “Effectiveness of antipsychotic drugs in patients with chronic schizophrenia”. N. Engl. J. Med. 353 (12): 1209–23. doi:10.1056/NEJMoa051688. PMID 16172203.
- ^ a b Findling RL, Johnson JL, McClellan J, et al. (June 2010). “Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study”. J Am Acad Child Adolesc Psychiatry 49 (6): 583–94; quiz 632. doi:10.1016/j.jaac.2010.03.013. PMC 2882800. PMID 20494268.
- ^ Makhinson, Michael (January 2010). “Biases in Medication Prescribing: The Case of Second-Generation Antipsychotics”. Journal of Psychiatric Practice 16 (1): 15–21. doi:10.1097/01.pra.0000367774.11260.e4. PMID 20098227.
- ^ Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM (2013-09-14). “Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis”. en:The Lancet 382 (9896): 951-62. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019.
- ^ a b Sogawa R, Shimomura Y, Minami C, Maruo J, Kunitake Y, Mizoguchi Y, Kawashima T, Monji A, Hara H. (2016-8). “Aripiprazole-Associated Hypoprolactinemia in the Clinical Setting.”. en:Journal of Clinical Psychopharmacology. 36 (4): 385-7. doi:10.1097/JCP.0000000000000527. PMID 27281387.
- ^ FDA Drug Safety Communication: FDA warns about new impulse-control problems associated with mental health drug aripiprazole (Abilify, Abilify Maintena, Aristada) (05-03-2016 FDA)
- ^ Moore TJ, Glenmullen J, Furberg CD. (2010-12-15). “Prescription drugs associated with reports of violence towards others.”. PLoS One. 5 (12): e15337. doi:10.1371/journal.pone.0015337. PMC 3002271. PMID 21179515.
- ^ Seeman P, Ko F, Tallerico T. (2005-9). “Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics.”. en:Molecular Psychiatry. 10 (9): 877-83. doi:10.1038/sj.mp.4001682. PMID 15852061.
- ^ Seeman P, Guan HC, Hirbec H. (2009-8). “Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil.”. en:Synapse. 63 (8): 698-704. doi:10.1002/syn.20647. PMID 19391150.
- ^ Ilyin, VI; Whittemore, ER; Guastella, J; Weber, E; Woodward, RM (1996). “Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol”. en:Molecular Pharmacology 50 (6): 1541-50. PMID 8967976.
- ^ a b エリオット・S・ヴァレンスタイン 2008, pp. 27–28.
- ^ デイヴィッド・ヒーリー 2012, p. 113.
- ^ a b デイヴィッド・ヒーリー 2012, p. 223-225.
- ^ Miller, G. (July 2010). “Is Pharma Running Out of Brainy Ideas?” (pdf). Science 329 (5991): 502–504. doi:10.1126/science.329.5991.502. PMID 20671165.
- ^ a b Pipeline antipsychotic drugs to drive next market evolution (2009). Healthcarefinancenews.com (7 August 2009).
- ^ Aparasu, R. R.; Bhatara, V. (December 2006). “Antipsychotic Use and Expenditure in the United States”. Psychiatric Services 57 (12): 1693–1693. doi:10.1176/appi.ps.57.12.1693. PMID 17158480.
- ^ 2008 U.S. Sales and Prescription Information: Top Therapeutic Classes by U.S. Sales (PDF). Imshealth.com.
- ^ GPs under 'pressure' to issue neuroleptics, claims professor, Chemist + Druggist, 15 January 2009
- ^ Nick Triggle (2009年11月12日). “Dementia drug use 'killing many'”. BBC 2013年5月7日閲覧。
- ^ “UK study warns against anti-psychotics for dementia”. reuters. (2009年11月12日) 2013年5月7日閲覧。
- ^ Hilzenrath, David S. (2010年1月16日). “Justice suit accuses Johnson & Johnson of paying kickbacks”. The Washington Post 2010年1月17日閲覧。
- ^ a b Jobe TH, Harrow M (December 2005). “Long-term outcome of patients with schizophrenia: a review” (PDF). Canadian Journal of Psychiatry 50 (14): 892–900. PMID 16494258. オリジナルの2011年7月25日時点におけるアーカイブ。 2008年7月5日閲覧。.
- ^ Kane, JM.; Leucht, S. (Mar 2008). “Unanswered Questions in Schizophrenia Clinical Trials”. Schizophr Bull 34 (2): 302–9. doi:10.1093/schbul/sbm143. PMC 2632396. PMID 18199633.
- ^ a b c Wilson, Duff (2010年10月2日). “Side Effects May Include Lawsuits”. New York Times. 2012年1月5日閲覧。
- ^ DUFF WILSON (2009年2月27日). “Drug Maker’s E-Mail Released in Seroquel Lawsuit”. The New York Times. The New York Times Company. 2012年7月27日閲覧。
- ^ Gosden R, Beder S (2001). “Pharmaceutical industry agenda setting in mental health policies”. Ethical Human Sciences and Services : an International Journal of Critical Inquiry 3 (3): 147–59. PMID 15278977.
- ^ Alex Berenson (2007年1月4日). “Lilly to Pay Up to $500 Million to Settle Claims”. The New York Times 2013年3月15日閲覧。
- ^ a b c Robert Whitaker 2009, pp. 355–357 （翻訳書は ロバート・ウィタカー 2010, pp. 528–531）
- ^ a b Peter C. Gøtzsche 2015, § Forced treatment must be banned
- ^ a b “Supreme Court of Alaska. No. S-11021.”. Thomson Reuters (2006年6月30日). 2018年7月2日閲覧。
- ^ a b “Alaska Forced Medication Case”. Law Project for Psychiatric Rights. 2018年7月2日閲覧。
- ^ “#07-782: 09-28-07 Bristol-Myers Squibb to Pay More Than $515 Million to Resolve Allegations of Illegal Drug Marketing and Pricing”. Justice.gov (2007年9月28日). 2012年11月30日閲覧。
- ^ “Pharmaceutical Company Eli Lilly to Pay Record $1.415 Billion for Off-Label Drug Marketing” (pdf). Justice.gov (2009年1月15日). 2012年10月17日時点のオリジナルよりアーカイブ。2013年2月23日閲覧。
- ^ “Pharmaceutical Company Pfizer, Inc. To Pay $301 Million for Off-Label Drug Marketing”. Justice.gov (2009年9月2日). 2013年2月23日閲覧。
- ^ “Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-label Drug Marketing”. Justice.gov (2010年4月27日). 2012年11月30日閲覧。
- ^ Michael Muskal (2012年4月11日). “Companies belittled risks of Risperdal, slapped with huge fine”. Los Angels Times 2013年2月23日閲覧。
- ^ Rohleder, Cathrin; Müller, Juliane K.; Lange, Bettina; et al. (2016). “Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence”. Frontiers in Pharmacology 7: 422. doi:10.3389/fphar.2016.00422. PMC 5099166. PMID 27877130.
- ^ World Health Organization; 日本臨床カンナビノイド学会 (6 December 2017). カンナビジオール（CBD）事前審査報告書 (pdf) (Report). 世界保健機関. p. 18. 2017年12月5日閲覧。 日本臨床カンナビノイド学会 World Health Organization (6 December 2017). CANNABIDIOL Pre-Review Report Agenda Item 5.2 : Expert Committee on Drug Dependence Thirty-ninth Meeting (pdf) (Report). 世界保健機関. 2017年12月5日閲覧。
- ^ a b Guinguis R, Ruiz MI, Rada G (2017-08-09). “Is cannabidiol an effective treatment for schizophrenia?”. Medwave. 17 (7): e7010. doi:10.5867/medwave.2017.07.7010. PMID 28820868.
- ^ McGuire, Philip; Robson, Philip; Cubala, Wieslaw Jerzy; et al. (2017). “Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial”. American Journal of Psychiatry: appi.ajp.2017.1. doi:10.1176/appi.ajp.2017.17030325. PMID 29241357.
- ^ Pawełczyk, Tomasz; Grancow, Marta; Kotlicka-Antczak, Magdalena; et al. (2015). “Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods”. BMC Psychiatry 15 (1): 97. doi:10.1186/s12888-015-0473-2. PMC 4456694. PMID 25934131.
- ^ “Microglia and Brain Plasticity in Acute Psychosis and Schizophrenia Illness Course: A Meta-Review”. Front Psychiatry 8: 238. (2017-11-16). doi:10.3389/fpsyt.2017.00238. PMC 5696326. PMID 29201010.
- ^ “Increased microglial synapse elimination in patient-specific models of schizophrenia”. BioRxiv. (2017-12-8). doi:10.1101/231290.
- ^ 厚生労働省健康局結核感染症課 (June 2017). 抗微生物薬適正使用の手引き 第一版 (pdf) (Report). 厚生労働省. 2017年12月10日閲覧。
[続きの解説]
「抗精神病薬」の続きの解説一覧
- Antipsychoticのページへのリンク
